Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers including prostate, lung, breast, ovarian, bladder, renal, pancreatic, multiple myeloma and liver cancer.
Investigated for use/treatment in cancer/tumors (unspecified).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.